Trial Profile
A Phase II open-label single-center study of the clinical activity and safety of the braf-v600 inhibitor vemurafenib (zelboraf) in combination with the b-cell targeting antibody rituximab (mabthera) in previously treated patients with hairy cell leukemia (hcl) carrying the braf-v600e mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Vemurafenib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 13 May 2021 Primary endpoint (Complete response at the end of planned treatment) has been met, according to results published in The New England journal of medicine.
- 13 May 2021 Status changed to completed, according to results published in the New England Journal of Medicine.
- 13 May 2021 Results published in the New England Journal of Medicine.